The Latest Cardiac and Vascular News
IRVINE, Calif., Sept. 26, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE :EW ), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced at a 60th anniversary educational event that the Every Heartbeat Matters initiative has exceeded the goal to impact the global burden of heart valve disease […]
IRVINE, Calif., July 26, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2018. Second Quarter and Recent Highlights: Sales grew 12 percent; underlying1 sales grew 10 percent Global THVT sales grew […]
IRVINE, Calif., July 12, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans to announce its operating results for the quarter ended June 30, 2018 after the market closes on Thursday, July 26, 2018, and will host a conference call at 5:00 p.m. […]
IRVINE, Calif., May 14, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will host its Annual Meeting of Stockholders on Thursday, May 17, 2018 beginning at 10:00 a.m. PT (1:00 pm ET) at its corporate headquarters in Irvine, California. A live webcast of the […]
IRVINE, Calif., April 24, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended March 31, 2018. First Quarter and Recent Highlights: Sales were $895 million, or $938 million on an adjusted basis Global THVT sales […]
MARLBOROUGH, Mass., April 16, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that it, along with several other opponents, successfully opposed Edwards Lifesciences Corporation’s European patent EP 2,399,550 (‘550) in the European Patent Office (EPO), resulting in a revocation of the patent. The ‘550 patent was the only Edwards patent that […]
IRVINE, Calif., April 10, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans to announce its operating results for the quarter ended March 31, 2018 after the market closes on Tuesday, April 24, 2018, and will host a conference call at 5:00 p.m. […]
WASHINGTON, March 23, 2018 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the United States Patent and Trademark Office (USPTO) decided in Edwards’ favor in an Inter Partes Review (IPR) of Boston Scientific’s U.S. transcatheter heart valve patent, […]
IRVINE, Calif., March 21, 2018 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that enrollment is complete in the computed tomography (CT) imaging sub-study within the PARTNER 3 trial of the SAPIEN 3 valve. This randomized sub-study is examining […]
IRVINE, Calif., Jan. 18, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans to announce its operating results for the quarter ended December 31, 2017 after the market closes on Thursday, February 1, 2018, and will host a conference call at 5:00 p.m. […]
